Summit Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Jul 23, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 23, 2026
SMMT$17.83-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders' Equity
(in thousands, except share data)
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares · Amount | ||||||||
| Balance at December 31, 2025 | 775,371,200 | $7,754 | $2,947,805 | $(2,540) | $(2,294,159) | $658,860 | ||
| Issuance of common stock under stock purchase plans and exercise of stock options | 646,274 | 6 | 3,791 | — | — | 3,797 | ||
| Stock-based compensation | — | — | 72,791 | — | — | 72,791 | ||
| Net other comprehensive loss | — | — | — | (92) | — | (92) | ||
| Net loss | — | — | — | — | (189,424) | (189,424) | ||
| Balance at March 31, 2026 | 776,017,474 | $7,760 | $3,024,387 | $(2,632) | $(2,483,583) | $545,932 | ||
| Issuance of common stock upon exercise of stock options | 670,453 | 7 | 3,658 | — | — | 3,665 | ||
| Proceeds from at-the-market offering, net of commissions of $3,463 (2) | 16,432,435 | 164 | 227,249 | — | — | 227,413 | ||
| Stock-based compensation | — | — | 68,706 | — | 68,706 | |||
| Net other comprehensive loss | — | — | — | (33) | — | (33) | ||
| Net loss | — | — | — | — | (215,700) | (215,700) | ||
| Balance at June 30, 2026 | 793,120,362 | $7,931 | $3,324,000 | $(2,665) | $(2,699,283) | $629,983 | ||
| Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders' Equity | |||||||
|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||
| Balance at December 31, 2024 | 737,626,004 | $7,376 | $1,598,230 | $(2,285) | $(1,214,573) | $388,748 | |
| Issuance of common stock under stock purchase plans and exercise of stock options and warrants (2) | 3,983,386 | 40 | 7,637 | — | — | 7,677 | |
| Stock-based compensation | — | — | 11,096 | — | — | 11,096 | |
| Net other comprehensive loss | — | — | — | (278) | (278) | ||
| Net loss | — | — | — | — | (62,913) | (62,913) | |
| Balance at March 31, 2025 | 741,609,390 | $7,416 | $1,616,963 | $(2,563) | $(1,277,486) | $344,330 | |
| Issuance of common stock upon exercise of stock options and warrants (2) | 1,197,282 | 12 | 2,210 | — | — | 2,222 | |
| Stock-based compensation | — | — | 478,784 | — | — | 478,784 | |
| Net other comprehensive loss | — | — | — | (189) | — | (189) | |
| Net loss | — | — | — | — | (565,708) | (565,708) | |
| Balance at June 30, 2025 | 742,806,672 | $7,428 | $2,097,957 | $(2,752) | $(1,843,194) | $259,439 | |
(2) Refer to Note 11 – Related Party Transactions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.